Farlow M R
Department of Neurology, Indiana University School of Medicine, Indianapolis 46202-5111, USA.
Neurology. 1997 May;48(5 Suppl 6):S30-4. doi: 10.1212/wnl.48.5_suppl_6.30s.
Inheritance of the apolipoprotein E (APOE = gene; apoE = protein) epsilon 4 gene is associated with a higher risk for development of Alzheimer's disease (AD) and for occurrence of this illness at a younger age. APOE gene dose and genotype interact with gender, ethnicity, and age to influence the probability of developing AD, as well as the rate of disease progression. The sensitivity and specificity of APOE genotyping, however, and the longer-term implications of the epsilon 4 allele as a susceptibility factor for AD, are not yet adequately understood to recommend the use of APOE genotyping in genetic counseling of asymptomatic family members of AD patients. Insufficient evidence also exists at this time to recommend APOE genotyping as an adjuvant for the differential diagnosis of dementia or as a possible predictor for response to drug therapy. These potential future clinical indications for apoE genotyping are under active investigation.
载脂蛋白E(APOE = 基因;apoE = 蛋白质)ε4基因的遗传与患阿尔茨海默病(AD)的较高风险以及在较年轻时患此病有关。APOE基因剂量和基因型与性别、种族和年龄相互作用,影响患AD的概率以及疾病进展速度。然而,APOE基因分型的敏感性和特异性,以及ε4等位基因作为AD易感性因素的长期影响,目前尚未得到充分了解,因此不建议在AD患者无症状家庭成员的遗传咨询中使用APOE基因分型。目前也没有足够的证据推荐将APOE基因分型作为痴呆鉴别诊断的辅助手段或作为药物治疗反应的可能预测指标。这些apoE基因分型未来可能的临床应用正在积极研究中。